2 dividend heroes with yields over 5% I’d buy now

These two stocks have high dividend yields and here’s why I think they can maintain them.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

High dividend yields aren’t always a good thing. We all want to chase the highest paying stock, but sometimes that isn’t the best course of action. That’s because struggling companies might boost the yield to attract investors and sometimes the yield is high simply because the share price has fallen due to the company struggling.

So dividend sustainability is key. Can the business afford its dividend or is a cut on the horizon? A company’s recent history will tell you whether the dividend is sustainable and if the stock is worth your money. Here are two I think are worth the price.

Pharmaceutical giant

GlaxoSmithKline (LSE: GSK) is my first pick, with its tempting dividend yield of 5.5%. It is currently priced at around 1,600p with a P/E ratio of around 20, not the best-looking P/E in the world, but I believe that even with its high price it can still reward investors. GlaxoSmithKline has steadily been paying dividend yields of around 5% to 6% for years now, reliably paying around 80p per share year after year. This reassures me that, despite market fluctuations, GSK can still bring in the money.

Such a high dividend could fluctuate, but CFO Iain MacKay has confirmed GSK’s commitment to the yield for this year. And the future? It has many products that are seeing great results with Ellipta respiratory sales climbing 20% and Nucala seeing 40% growth in Q1 this year. The company has three main areas of income that provide a safety net: consumer healthcare, vaccines and pharmaceuticals. Vaccines sales soared in Q1 due to the Shingrix shingles treatment. This vaccine accounted for £365m of sales, up from £110m in Q1 of 2018, which is more than a fifth of all vaccine revenue for the firm. Vaccine sales as a whole were up 23% in Q1. This huge amount of cash flow helps sustain a healthy dividend yield I believe is worth paying a high price for.

Reality show

ITV (LSE: ITV) is my next pick, with its mouthwatering yield of 7.6%. ITV shares are currently priced around 106p with a P/E ratio of 11.9. That ratio is lower than the UK average and the company has reasonable long-term debt levels of £981m with £424m operating cash flow in the last 12 months. This means an operating-cash-to-total-debt ratio of 40%, demonstrating how the debt is significantly covered.

ITV did well in Q1. Despite total national television viewers dropping 3%, its share of these views rose 24%. Registered ITV hub users have also risen by 29% this year, with statistics showing that there’s at least one ITV hub account in every UK household. These figures highlight how the company has an in-depth share of (and insight into) our TV habits. This is important as it plans to launch targeted ads on the hub accounts that should hopefully boost revenue this year, reassuring investors, despite the challenging TV advertising market.

Furthermore, the return of Love Island has also seen a huge boost in viewership, keeping ITV ahead during prime time TV hours. That upcoming launch of ITV hub tailored ads and an admittedly-modest 1% increase in revenues in Q1 shows the company has growth prospects ahead. With ITV stock prices being so low and a healthy dividend, I think that this undervalued investment is far too tempting to ignore. 

fional has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended ITV. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Can someone invest like Warren Buffett with a spare £500?

Christopher Ruane explains why an investor without the resources of billionaire Warren Buffett could still learn from his stock market…

Read more »

Investing Articles

Can these 2 incredible FTSE 250 dividend stocks fly even higher in 2026?

Mark Hartley examines the potential in two FTSE 250 shares that have had an excellent year and considers what 2026…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Is 45 too late to start investing?

Investing at different life stages can come with its own challenges -- and rewards. Our writer considers why a 45-year-old…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

UK shares look cheap — but the market might be about to take notice

UK shares have traded at a persistent discount to their US counterparts. This can create huge opportunities, but investors need…

Read more »

Investing Articles

This FTSE 100 growth machine is showing positive signs for a 2026 recovery

FTSE 100 distributor Bunzl is already the second-largest holding in Stephen Wright’s Stocks and Shares ISA. What should his next…

Read more »

Investing Articles

I asked ChatGPT for the best FTSE 100 stocks to buy for passive income in 2026 and it said…

Paul Summers wanted to learn which dividend stocks an AI bot thinks might be worth buying for 2026. Its response…

Read more »

ISA Individual Savings Account
Investing Articles

Stop missing out! A Stocks and Shares ISA could help you retire early

Investors who don't use a Stocks and Shares ISA get all the risks that come with investing but with less…

Read more »

Investing Articles

Will Greggs shares crash again in 2026?

After a horrible 2025, Paul Summers takes a look at whether Greggs shares could sink even further in price next…

Read more »